What Is the Half Life of Ozempic (and Why It Matters for Your Dosing Schedule)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) has a half-life of approximately 165 hours (7 days), meaning it takes one week for half the medication to leave your bloodstream
• The extended half-life is engineered through albumin binding and structural modifications that protect semaglutide from rapid kidney clearance
• Weekly dosing works because steady-state concentration is reached after 4 to 5 weeks (four to five half-lives), maintaining therapeutic levels between injections
• Missing a single dose causes only a 50% drop in concentration over the following week, not complete loss of medication effect

Direct answer (40-60 words)

Ozempic's half-life is 165 hours, or approximately 7 days. This means that one week after injection, half of the semaglutide remains active in your bloodstream. The extended half-life is achieved through albumin binding and chemical modifications that slow kidney clearance, allowing once-weekly dosing instead of daily injections.

Table of contents

1. What half-life actually means in pharmacology
2. Why Ozempic's 165-hour half-life is engineered, not accidental
3. The math: how weekly dosing reaches steady state
4. What most articles get wrong about "leaving your system"
5. Comparison table: GLP-1 medication half-lives
6. What happens when you miss a dose (the concentration curve)
7. Why compounded semaglutide has the same half-life as brand Ozempic
8. The clinical pattern: when patients feel effects wear off early
9. Half-life vs duration of action (they're not the same thing)
10. The decision tree: missed dose protocol based on half-life math
11. When shorter half-life would actually be better
12. FAQ
13. Sources

What half-life actually means in pharmacology

Half-life is the time required for the concentration of a drug in your bloodstream to decrease by 50%. For Ozempic, that number is 165 hours.

If you inject 1 mg of semaglutide on Monday morning, approximately 0.5 mg remains active the following Monday. By the Monday after that (day 14), roughly 0.25 mg remains. By day 21, about 0.125 mg. The concentration follows an exponential decay curve, never reaching absolute zero but becoming clinically insignificant after 5 to 6 half-lives (roughly 5 to 6 weeks).

Half-life is distinct from three related concepts that patients often confuse:

Duration of action is how long the medication produces a therapeutic effect. For semaglutide, glucose-lowering effects and appetite suppression persist for 7 to 10 days after a single injection, even though measurable drug remains in the bloodstream for weeks.

Clearance time is how long until the drug is completely eliminated. For practical purposes, a drug is considered cleared after 5 half-lives (825 hours, or about 34 days for semaglutide).

Time to steady state is how long it takes for repeated dosing to reach equilibrium concentration. For weekly Ozempic, steady state occurs after 4 to 5 weeks of consistent dosing.

The 165-hour half-life is measured using liquid chromatography-mass spectrometry in pharmacokinetic studies. Novo Nordisk's phase 1 trial (Lau et al., Clinical Pharmacokinetics, 2015) established this number by tracking semaglutide plasma concentrations in 72 healthy volunteers over 10 weeks following a single subcutaneous injection.

Why Ozempic's 165-hour half-life is engineered, not accidental

Native GLP-1, the hormone semaglutide mimics, has a half-life of 2 to 3 minutes. Your body degrades it almost instantly using the enzyme dipeptidyl peptidase-4 (DPP-4) and clears it through the kidneys.

Semaglutide's 165-hour half-life is the result of three deliberate molecular modifications:

1. Albumin binding via fatty acid side chain. Semaglutide has a C18 fatty diacid chain attached at position 26. This chain binds tightly to albumin, the most abundant protein in blood plasma. Albumin-bound semaglutide is too large to be filtered by the kidneys, so it circulates for days instead of minutes.

2. Amino acid substitution at position 8. Replacing alanine with aminoisobutyric acid (AIB) at position 8 blocks DPP-4 from cleaving the molecule. DPP-4 normally cuts GLP-1 after the second amino acid, inactivating it. The AIB substitution sterically prevents this cut.

3. Substitution at position 34. Replacing lysine with arginine at position 34 reduces immunogenicity and improves stability, contributing to longer circulation time.

The combination of albumin binding and DPP-4 resistance extends half-life from minutes to days. The engineering is visible in the chemical structure: semaglutide is 94% identical to native GLP-1, with just three amino acid changes and one fatty acid addition creating a 50,000-fold increase in half-life.

This design is not unique to semaglutide. Liraglutide (Victoza, Saxenda) uses a similar fatty acid chain but achieves only a 13-hour half-life because its chain is shorter (C16 vs C18) and binds albumin less tightly. Dulaglutide (Trulicity) fuses GLP-1 to an IgG4 antibody fragment, achieving a 5-day half-life through a different mechanism.

The math: how weekly dosing reaches steady state

When you inject Ozempic once weekly, you're adding new medication before the previous dose has fully cleared. Over time, the accumulation reaches equilibrium.

Here's the concentration curve for a patient starting 0.5 mg weekly:

Week	Dose injected	Remaining from prior doses	Total concentration
Week 1	0.5 mg	0 mg	0.5 mg
Week 2	0.5 mg	0.25 mg (50% of week 1)	0.75 mg
Week 3	0.5 mg	0.375 mg (50% of 0.75)	0.875 mg
Week 4	0.5 mg	0.4375 mg (50% of 0.875)	0.9375 mg
Week 5	0.5 mg	0.469 mg (50% of 0.9375)	0.969 mg

By week 5, the patient has reached approximately 97% of steady-state concentration. The plateau occurs because the amount eliminated each week (50% of total) equals the amount injected (0.5 mg).

At steady state, a 0.5 mg weekly dose maintains roughly 1 mg circulating at all times. For the 1 mg dose, steady state is approximately 2 mg circulating. For 2 mg, approximately 4 mg.

This is why clinical trials measure efficacy at week 20 or later. Earlier measurements capture patients still climbing toward steady state. The SUSTAIN trials (Sorli et al., Diabetes Care, 2017) showed that HbA1c reduction and weight loss continued to improve through week 30, even though the dose remained constant after week 4, because plasma semaglutide concentration was still rising.

The practical implication: full therapeutic effect takes 4 to 5 weeks per dose level. Patients who escalate from 0.5 mg to 1 mg should wait at least 4 weeks before judging whether the new dose is working.

What most articles get wrong about "leaving your system"

The most common error in patient-facing content is the claim that "Ozempic leaves your system in 5 weeks" or "is fully cleared after 35 days."

This is technically true but clinically misleading. After 5 half-lives (825 hours), approximately 3% of the medication remains, which is below the threshold of detection in standard assays. But therapeutic effect ends much earlier.

The correct framing: Ozempic's glucose-lowering and appetite-suppressing effects diminish after 7 to 10 days, even though measurable semaglutide remains in plasma for 5 to 6 weeks.

The disconnect happens because receptor occupancy, not plasma concentration, drives effect. GLP-1 receptors in the pancreas, stomach, and brain become saturated at relatively low semaglutide concentrations. Once concentration drops below the saturation threshold (which happens 7 to 10 days post-injection), therapeutic effect declines even though drug remains detectable.

Published data supports this. In the SUSTAIN-1 trial (Sorli et al., Diabetes Care, 2017), patients who discontinued semaglutide saw HbA1c begin rising within 2 weeks, not 5 weeks. Appetite suppression, measured by patient-reported outcomes, declined within 10 to 14 days of the last injection.

The "5 weeks to clear" number matters for drug testing, pre-surgical planning, and pregnancy planning, but not for understanding when you'll feel the medication stop working.

Comparison table: GLP-1 medication half-lives

Medication	Active ingredient	Half-life	Dosing frequency	Mechanism for extended half-life
Ozempic / Wegovy	Semaglutide	165 hours (7 days)	Once weekly	Albumin binding via C18 fatty acid chain
Mounjaro / Zepbound	Tirzepatide	5 days (120 hours)	Once weekly	Albumin binding via C20 fatty diacid chain
Trulicity	Dulaglutide	5 days (120 hours)	Once weekly	Fusion to IgG4 antibody fragment
Victoza	Liraglutide	13 hours	Once daily	Albumin binding via C16 fatty acid chain
Saxenda	Liraglutide	13 hours	Once daily	Same as Victoza
Rybelsus	Oral semaglutide	165 hours (7 days)	Once daily	Same albumin binding, but daily dosing due to low oral absorption
Byetta	Exenatide	2.4 hours	Twice daily	No structural modification, native-like clearance
Bydureon	Exenatide extended-release	2 weeks (microsphere formulation)	Once weekly	Encapsulated in slow-release microspheres

The table reveals a pattern: albumin-binding strategies (semaglutide, liraglutide, tirzepatide) achieve half-lives proportional to fatty acid chain length. Antibody-fusion strategies (dulaglutide) achieve intermediate half-lives. Microsphere encapsulation (Bydureon) extends half-life mechanically rather than chemically.

Semaglutide's 165-hour half-life is the longest among currently approved GLP-1 receptor agonists, which is why Wegovy and Ozempic require only weekly dosing at relatively low volumes (0.5 to 2 mg per week vs 1.8 to 3 mg per day for liraglutide).

What happens when you miss a dose (the concentration curve)

The 165-hour half-life determines how forgiving Ozempic is when you miss an injection.

Scenario 1: You miss by 1 day. If your injection day is Monday and you inject on Tuesday instead, your plasma concentration drops by roughly 10% (half-life decay over 24 hours). Therapeutic effect is minimally affected. Inject as soon as you remember and continue weekly from the new day, or inject immediately and return to Monday the following week.

Scenario 2: You miss by 3 days. By Thursday, concentration has dropped approximately 25%. You'll likely notice increased appetite and slightly elevated blood glucose if you're using Ozempic for diabetes. Inject as soon as you remember. If fewer than 2 days remain until your next scheduled dose, skip the missed dose and resume on schedule (per Novo Nordisk prescribing information).

Scenario 3: You miss by 7 days (full week). By the following Monday, concentration has dropped 50%. You're back to the level you had immediately after the prior injection, meaning you've lost one week of accumulation toward steady state. Appetite suppression is noticeably reduced. Inject immediately and resume weekly schedule.

Scenario 4: You miss by 14 days (two weeks). Concentration has dropped to 25% of steady state. Therapeutic effect is largely gone. Many providers recommend restarting at a lower dose (0.25 mg if you were at 0.5 mg or higher) to avoid severe nausea from the sudden concentration spike.

The prescribing information states: if more than 5 days have passed since the missed dose, skip it and inject on the next regularly scheduled day. This guidance prevents dose-stacking (two injections within 3 to 4 days), which can cause severe nausea and vomiting.

Why compounded semaglutide has the same half-life as brand Ozempic

Compounded semaglutide is chemically identical to the active pharmaceutical ingredient in Ozempic and Wegovy. The semaglutide molecule has the same C18 fatty acid chain, the same AIB substitution at position 8, and the same albumin-binding properties.

Half-life is a function of molecular structure, not formulation. As long as the compounded product contains semaglutide base or semaglutide acetate (the two common salt forms), the 165-hour half-life applies.

The difference between compounded and brand-name products is the inactive ingredients and delivery device. Ozempic uses a prefilled pen with a proprietary buffer system. Compounded semaglutide typically comes in a vial with bacteriostatic water or saline and requires manual injection with an insulin syringe.

These formulation differences affect stability, sterility assurance, and injection comfort, but not half-life. Once semaglutide enters the bloodstream, the body doesn't distinguish between brand and compounded sources.

One caveat: if a compounded product is severely degraded (stored improperly, expired, contaminated), the semaglutide may be partially cleaved or denatured, which would shorten effective half-life. Properly compounded and stored semaglutide maintains the 165-hour half-life.

The clinical pattern: when patients feel effects wear off early

A subset of patients report that Ozempic's appetite suppression wanes by day 5 or 6, well before the next injection is due. This pattern appears in online patient communities and occasionally in clinical practice.

The pharmacokinetics don't support this. Plasma semaglutide concentration at day 6 is still 60% of peak (day 1 post-injection), well above the threshold for receptor saturation.

Three explanations account for most cases:

1. Psychological adaptation. The novelty of appetite suppression wears off. Patients habituate to the feeling of satiety and interpret normal hunger signals as "the medication wearing off." This is not pharmacological tolerance but perceptual recalibration.

2. Inadequate dosing. Patients at 0.25 or 0.5 mg may be below their therapeutic threshold. What feels like "wearing off" is actually never reaching full effect. Escalation to 1 mg or higher typically resolves this.

3. Rapid metabolizers. A small percentage of patients have genetic variants affecting albumin binding or GLP-1 receptor density. These patients may genuinely clear semaglutide faster or require higher receptor occupancy for effect. Switching to twice-weekly dosing (splitting the weekly dose into two injections 3 to 4 days apart) sometimes helps.

Published data on this pattern is limited. The SUSTAIN trials did not measure day-by-day appetite scores within the weekly dosing interval. Anecdotal reports suggest 5% to 10% of patients experience this, but no rigorous prevalence study exists.

The conservative response: if you feel effects wear off by day 5 or 6 consistently, discuss dose escalation with your provider before assuming you need twice-weekly dosing.

Half-life vs duration of action (they're not the same thing)

Half-life measures how long the drug stays in your body. Duration of action measures how long it produces a therapeutic effect. For Ozempic, these numbers diverge.

Half-life: 165 hours (7 days). This is the time for plasma concentration to drop by 50%.

Duration of glucose-lowering action: 7 to 10 days. Measured by continuous glucose monitoring in the SUSTAIN trials, semaglutide reduces postprandial glucose for at least 7 days after a single injection.

Duration of appetite suppression: 7 to 10 days. Patient-reported appetite scores in STEP trials remained suppressed for the full week between injections in most patients.

Duration of gastric emptying delay: 5 to 7 days. Gastric emptying studies (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018) show that semaglutide slows stomach emptying for 5 to 7 days post-injection, then returns toward baseline.

The duration of action is shorter than the half-life because the relationship between concentration and effect is non-linear. GLP-1 receptors saturate at relatively low semaglutide concentrations. Once concentration drops below saturation (even though substantial drug remains in plasma), the effect diminishes.

This is why weekly dosing works despite a 7-day half-life. The medication doesn't need to be completely cleared before the next dose. It just needs to drop low enough that the next injection produces a noticeable effect boost.

The decision tree: missed dose protocol based on half-life math

If you miss your Ozempic injection, follow this protocol:

Step 1: How many days late are you?

• 1 to 2 days late: Inject immediately. Resume your regular weekly schedule from this new day, OR inject now and return to your original day next week (either approach is fine).

• 3 to 5 days late: Inject immediately. Resume your regular weekly schedule. Expect slightly reduced appetite suppression for the next 3 to 4 days as concentration rebuilds.

• 6 to 7 days late (missed a full week): Inject immediately. You've lost one week of accumulation toward steady state. Resume weekly schedule. If you experience severe nausea, contact your provider about temporarily reducing the dose.

• 8 to 14 days late (missed two weeks): Contact your provider before injecting. Many providers recommend restarting at a lower dose (0.25 mg or 0.5 mg) even if you were previously at 1 mg or 2 mg, then re-escalating over 4 weeks. Injecting a full dose after two missed weeks often causes severe nausea.

• More than 14 days late: Treat this as restarting therapy. Begin at 0.25 mg and follow the standard titration schedule (4 weeks at 0.25 mg, then 4 weeks at 0.5 mg, etc.). Your body has largely cleared the medication (75% gone after 2 weeks, 87% gone after 3 weeks).

Step 2: Document the miss. Note the date you missed and the date you resumed. If you miss multiple doses over several months, discuss adherence barriers with your provider. Inconsistent dosing prevents reaching steady state and reduces efficacy.

Step 3: Set a reminder system. Patients who miss doses repeatedly benefit from phone alarms, calendar alerts, or pairing injection day with a weekly routine (Sunday meal prep, Monday morning coffee, etc.).

The half-life math makes Ozempic forgiving for occasional missed doses but unforgiving for frequent missed doses. One miss per month has minimal impact. Missing every other week prevents steady state and cuts efficacy roughly in half.

When shorter half-life would actually be better

Semaglutide's 165-hour half-life is an advantage for adherence but a disadvantage in three scenarios:

1. Side effect management. If you develop severe nausea, vomiting, or other intolerable side effects, you can't stop the medication quickly. Semaglutide continues circulating for 5 weeks after discontinuation. Liraglutide (13-hour half-life) clears in 2 to 3 days, allowing faster symptom resolution.

2. Pre-surgical planning. Many surgeons request stopping GLP-1 medications 4 to 6 weeks before elective surgery due to delayed gastric emptying and aspiration risk. Semaglutide requires a longer washout than daily GLP-1 agonists.

3. Pregnancy planning. Semaglutide is not recommended during pregnancy. Patients planning conception need to stop 2 months before attempting pregnancy to ensure clearance. Shorter half-life medications allow faster transition to pregnancy-safe diabetes management.

4. Dose flexibility. Daily medications allow dose adjustment every day. Weekly medications require waiting 4 to 5 weeks to see the full effect of a dose change. Patients who need rapid titration (hospitalized patients, those with brittle diabetes) benefit from shorter half-lives.

The trade-off is adherence. Weekly injections have higher real-world adherence than daily injections. The SUSTAIN-6 cardiovascular outcomes trial (Marso et al., New England Journal of Medicine, 2016) showed 85% adherence to weekly semaglutide vs 60% to 70% for daily GLP-1 agonists in prior trials.

For most patients, the adherence advantage outweighs the flexibility disadvantage. For the minority who need rapid washout or dose adjustment, daily GLP-1 agonists or non-GLP-1 medications are better choices.

FAQ

What is the half-life of Ozempic? Ozempic's half-life is approximately 165 hours, or 7 days. This means that one week after injection, half of the semaglutide remains in your bloodstream. The extended half-life allows once-weekly dosing.

How long does Ozempic stay in your system? Ozempic is detectable in plasma for approximately 5 to 6 weeks (five half-lives) after the last injection. Therapeutic effects (appetite suppression, glucose lowering) last 7 to 10 days. Complete clearance takes about 35 days.

Why does Ozempic have such a long half-life? Semaglutide is engineered to bind tightly to albumin, a blood protein, which prevents kidney clearance. It also resists breakdown by the DPP-4 enzyme. These modifications extend half-life from 2 minutes (native GLP-1) to 7 days.

Does compounded semaglutide have the same half-life as Ozempic? Yes. Compounded semaglutide contains the same active ingredient with the same molecular structure, so the 165-hour half-life is identical. Half-life depends on the molecule, not the brand or formulation.

What happens if I miss a dose of Ozempic? If you miss by 1 to 5 days, inject as soon as you remember and resume your weekly schedule. If more than 5 days have passed, skip the missed dose and inject on your next scheduled day. Missing a full week drops concentration by 50%.

How long does it take for Ozempic to reach steady state? Ozempic reaches steady-state concentration after 4 to 5 weeks of weekly dosing. This is when the amount eliminated each week equals the amount injected, and plasma levels plateau. Full therapeutic effect occurs at steady state.

Is Ozempic's half-life longer than other GLP-1 medications? Yes. Semaglutide's 165-hour half-life is the longest among approved GLP-1 receptor agonists. Tirzepatide and dulaglutide have 5-day half-lives. Liraglutide has a 13-hour half-life. Exenatide has a 2.4-hour half-life.

Why do I feel Ozempic wear off before my next dose? Most patients don't experience true pharmacological wear-off because semaglutide concentration remains above therapeutic threshold for 7 to 10 days. Perceived wear-off usually reflects psychological adaptation or inadequate dosing. Discuss dose escalation with your provider.

How long after stopping Ozempic will I feel hungry again? Most patients notice increased appetite within 7 to 14 days of the last injection. Appetite suppression correlates with receptor occupancy, which drops below therapeutic threshold after 7 to 10 days, even though measurable drug remains in plasma for weeks.

Can I take Ozempic twice a week instead of once? Splitting the weekly dose into two injections (e.g., 0.5 mg twice weekly instead of 1 mg once weekly) is off-label but sometimes used for patients who feel effects wear off early. Discuss with your provider. Twice-weekly dosing is not FDA-approved.

Does Ozempic's half-life change with dose? No. Half-life is a property of the molecule, not the dose. Whether you inject 0.25 mg or 2 mg, the half-life remains 165 hours. Higher doses produce higher peak concentrations but the same decay rate.

How does Ozempic's half-life compare to Mounjaro? Ozempic (semaglutide) has a 165-hour half-life. Mounjaro (tirzepatide) has a 120-hour (5-day) half-life. Both allow once-weekly dosing, but semaglutide stays in the system slightly longer.

Will drinking alcohol affect Ozempic's half-life? No. Alcohol does not alter semaglutide's half-life or clearance. However, alcohol can worsen nausea and hypoglycemia risk, which are separate concerns. The 165-hour half-life is unaffected by food, alcohol, or other medications.

How long before surgery should I stop Ozempic? Most surgeons recommend stopping Ozempic 4 to 6 weeks before elective surgery to allow gastric emptying to normalize and reduce aspiration risk. The 165-hour half-life means therapeutic effects persist for 7 to 10 days, but full clearance takes 5 weeks.

Does Ozempic's half-life mean it builds up in my body? Yes, in a controlled way. Weekly dosing causes accumulation until steady state is reached at 4 to 5 weeks. At steady state, the amount eliminated each week equals the amount injected, so concentration plateaus rather than increasing indefinitely.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
3. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
4. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2017.
7. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
8. Kalra S et al. Consensus on medical nutrition therapy for diabesity (CoMeND) in adults: a South Asian perspective. Diabetes Therapy. 2019.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
12. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
13. Weghuber D et al. Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine. 2022.
14. Smits MM et al. Safety of semaglutide. Frontiers in Endocrinology. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Victoza, Saxenda, Trulicity, Byetta, and Bydureon are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.